Search 33,000+ CME courses
Back

Physicians’ Education Resource

  • Chemoradiotherapy
  • Cytokine Release Syndrome
  • Immunotherapy
  • Small Cell Lung Carcinoma

Community Oncology Connections(TM): Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | New Jersey Regional Program

Immunotherapy is reshaping the treatment landscape across the entire small cell lung cancer (SCLC) continuum, from limited-stage through relapsed disease. Three FDA approvals in the past 15 months-durvalumab consolidation after concurrent chemoradiotherapy in limited-stage SCLC (LS-SCLC), lurbinectedin plus atezolizumab as first-line maintenance in extensive-stage SCLC (ES-SCLC), and tarlatamab for relapsed disease-have introduced practice-changing options after decades of limited progress. As these therapies enter routine practice, it is vital for clinicians to stay current on the evolving clinical efficacy data, understand the distinctions between available regimens, and recognize the unique safety profiles and toxicity management strategies-including immune-mediated adverse events, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS)-associated with each approach. This program pairs an academic SCLC expert with a community oncologist to discuss the latest advances and enable the integration of immunotherapy across the SCLC continuum into community practice. Through interactive, case-based discussions between academic and community oncology colleagues, participants will gain practical insights and strategies to identify appropriate candidates for consolidation immunotherapy in limited-stage disease, navigate frontline chemoimmunotherapy backbone and maintenance decisions in extensive-stage disease, develop evidence-based sequencing approaches for relapsed SCLC, and proactively recognize and manage treatment-related adverse events to optimize patient outcomes. This educational activity is an archive of the live presentation held on September 22, 2026.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

No specific specialties targeted.

Pricing

Free

Reported to ACCME by the provider

  • Case-based learning
  • Credit · Up to 1.25 credits
  • Commercial Support
  • Released
    Oct 1, 2026
  • Last day to claim credit
    Nov 6, 2026 4 weeks left

Related courses

See all

Other providers’ courses on the same topic

More from Physicians’ Education Resource

See all

This provider’s courses closest to this one